AcoMed Completes Hundreds of Millions RMB Series B+ Financing to Advance Full-Portfolio Strategy in Neurointervention

VCBeat (WeChat ID: vcbeat) has learned that AccuMedical, a medical device company in the field of neurointervention, has announced the completion of its B+ round of financing, amounting to hundreds of millions of yuan.Led by HongShan, with participation from existing investor Huagai Capital and new investor Taikang Insurance Group, which is alsoInsurance Capital Enters the Market for the First TimeNeurointerventional field. The proceeds from the financing will be primarily used to comprehensively advance the company’s deployment of its full product portfolio for stroke care.

This financing round comes just six months after AccuMedical’s previous Series B funding. Both HongShan and Huagai Capital have participated in two consecutive rounds. As star investors in the healthcare sector, what core advantages does AccuMedical possess that have garnered their continued investment confidence? In addition to these firms, other investors behind AccuMedical includeBoyuan Capital，RatioLinXing Venturesand other well-known investors.

AccuMedical is a medical device company established in 2016. The company primarily focuses on the neurointerventional device sector and has developed a comprehensive product portfolio within this field, encompassing products for the treatment of hemorrhagic stroke, ischemic stroke, and access support devices.

Regarding this round of financing, the founder of AccuMedical responded, “The smooth development of an enterprise requires comprehensive support from industry experts and capital market partners. Since its inception, AccuMedical has been committed to providing neurologists with the safest and most effective interventional surgical devices. Through several representative initial product launches, we have been fortunate to gain recognition from clinicians, laying a solid foundation for further refinement and expansion of our product portfolio.”

“The Chinese neurointerventional market urgently requires domestic manufacturers to provide high-quality, internationally competitive products to meet supply demands. Subsequently, leveraging rapid clinical feedback, we aim to challenge the global technological frontier in certain unexplored areas. Merely adopting a ‘Copy to China’ strategy falls short of meeting market expectations for domestic manufacturers. Guided by insights from global clinical experts and powered by our dual-engine structure in China and the United States, we remain committed to delivering products with substantial clinical value to patients. We extend our sincere gratitude to both new and existing investors for their continued trust.”

China is the largest market for stroke-related medical demand. Approximately 7% of China’s adult population has intracranial aneurysms, and due to the risk of rupture and severe sequelae, treatment for this condition is an unequivocal medical necessity. In 2016, there were 13.7 million new stroke cases globally, with 5 million occurring in China, meaning that nearly four out of every ten stroke patients worldwide were from China. In terms of mortality, approximately 5.5 million people die from stroke annually worldwide, including 1.79 million in China, accounting for more than one-third of the global total.

Behind this enormous volume of cases lies a vast market for interventional stroke devices. From embolization coils to flow diverters, stent retrievers to aspiration catheters, and microcatheters to intermediate catheters, the majority of China’s expansive neurointerventional market share has been captured by foreign companies such as Medtronic, Stryker, Terumo, and Johnson & Johnson. However, in recent years, domestic brands have been on the rise, gradually emerging as new forces in the local neurointerventional industry. Medical device companies represented by AccuMedical have even achieved comprehensive coverage across the neurointerventional sector.

AccuMedical’s product portfolio includes:Hemorrhagic、IschemicandPathway CategoryThe product comprises three segments, delivering comprehensive solutions for clinical departments in the treatment of various cerebrovascular diseases. Meanwhile, it will serve as a profit-driving pillar for the company over the next five years, providing resilience against homogeneous competition and policy regulatory cycles.

Flow diverter devices have gained widespread trust among clinicians in recent years, with their use in clinical practice in China growing rapidly. Industry experts predict that within the next five years, 50–70% of endovascular procedures for intracranial aneurysms will rely on flow diverter treatment.

The company's most advanced pipelineFlow diverter has completed clinical trialsFlow diverter implantation is a novel interventional technique for the treatment of aneurysms and represents the latest generation of technology currently available internationally. After implantation, the flow diverter alters the hemodynamics of the parent artery, redirecting blood flow that would originally enter the aneurysm sac along the physiological direction of blood flow. This reduces the impact of blood flow on the aneurysm wall, thereby lowering the risk of rupture, while simultaneously avoiding the high recurrence rates and mass effect associated with simple coil embolization.

Acute Ischemic Stroke is another key area of focus in neurointerventional therapy.Intracranial Thrombectomy StentandIntracranial Thrombus Aspiration CatheterCombined mechanical thrombectomy techniques have gradually become a powerful tool for treating acute cerebral infarction, as demonstrated by multiple cohort clinical studies in recent years. In the 2015 updated guidelines for the management of acute ischemic stroke in both China and the United States, stent retrievers were given the highest level of recommendation. The research, development, and manufacturing of intracranial aspiration catheters are more challenging than those of intracranial stent retrievers, imposing extremely high requirements on anti-collapse performance, intraluminal coating, and trackability.

The company’s independently developed intracranial thrombectomy stent and intracranial thrombus aspiration catheter will together form the core components of its mechanical thrombectomy system, bringing transformative change to the field of acute ischemic stroke treatment.

Meanwhile, AccuMedical has overcome the technical limitations of imported products by iterating its intermediate catheters and microcatheters required for intracranial mechanical thrombectomy in conjunction with flow diverter devices. These products offer superior maneuverability and safety while maintaining compatibility with all commercially available devices, establishing them as next-generation, infrastructure-level products for neurointerventional procedures.

Regarding the investment in AccuMedical,Mr. Shen Nanpeng, Global Executive Partner at Sequoia Capital, the lead investor“The statement read: ‘Neuroscience represents another strategic high ground in the life and health sector, and the exploration and advancement of treatments for brain-related disorders constitute a key area of sustained focus and support for HongShan China Fund. We are impressed by AccuMedical’s comprehensive product portfolio in neurointervention, particularly its globally patented, first-in-class innovations developed for hemorrhagic cerebrovascular diseases. As the lead investor across multiple financing rounds, we look forward to seeing the company accelerate its product development under the support of HongShan China and other shareholders, thereby benefiting a broader population of patients with cerebrovascular diseases both in China and abroad.’”

Xu Xiaolin, Chairman and Founder of Huagai CapitalStatement: We are highly optimistic about the future development of the neurointerventional field in China. As a leading domestic enterprise in neurointervention, AccuMedical possesses strong competitiveness in product R&D, marketing networks, and medical resources. The company’s first neurointerventional product, the flow diverter, has demonstrated excellent performance and received unanimous acclaim from clinicians, holding the promise of breaking the monopoly held by international medical device manufacturers. Huagai Capital is highly bullish on the company’s comprehensive team structure and industry expertise, and will support AccuMedical in becoming a leader in the neurointerventional sector, thereby continuing to create value for society.

Mr. Duan Guosheng, Executive Vice President and CEO of Taikang Insurance Group, and CEO of Taikang Asset“Taikang Insurance Group, as a long-term and stable value investor, has been committed to building a comprehensive health ecosystem for the era of longevity. Stroke, characterized by high incidence and mortality rates in China, is a category of diseases that severely impacts the health of Chinese residents. Focusing on the field of stroke, AccuMedical has leveraged its globally leading technological capabilities to develop a full-range product portfolio with significant clinical value. The investment in AccuMedical represents Taikang’s strategic layout in the field of innovative neurointerventional medical devices. We hope this financing will support AccuMedical’s team in further intensifying product research and development, thereby enabling stroke patients to benefit from these advancements at an earlier date.”

Sequoia Capital has always been committed to helping entrepreneurs build enduring, great companies by bringing its member enterprises rich global resources and valuable historical experience. Over the past 48 years, Sequoia Capital has invested in numerous innovative enterprises and leaders shaping industry trends. As “entrepreneurs behind entrepreneurs,” Sequoia China focuses on investment opportunities in four sectors: technology/media, healthcare, consumer goods/services, and industrial technology. Over the past 15 years, Sequoia China has invested in nearly 600 companies characterized by distinct technological features, innovative business models, and high growth potential.

About Huagai Capital

Huagai Capital envisions becoming the most trusted investment partner for entrepreneurs and investors. It focuses on private equity investments in three major sectors: healthcare, TMT (Technology, Media, and Telecom), and culture and education. The firm has managed cumulative fund assets exceeding RMB 15 billion, with 12 portfolio companies successfully listed. Its healthcare fund concentrates on biopharmaceuticals, medical devices, and healthcare services, prioritizing industry M&A and consolidation opportunities as well as early- to mid-stage high-growth investments in high-tech enterprises within the healthcare sector.

Taikang Insurance Group, established in 1996, is one of China’s leading insurance and financial services groups, with business operations spanning three core sectors: insurance, asset management, and healthcare and elderly care. Healthcare represents a key investment focus for Taikang; in recent years, it has invested in multiple projects, including WuXi AppTec, Mindray Medical, Innovent Biologics, Sanbo Brain Hospital, and Donglei Brain Hospital.